RiboX wins FDA clearance for first circular RNA CAR therapy
RiboX Therapeutics received FDA IND clearance for RXIM002 the first circular RNA based in vivo CAR therapy for autoimmune cytopenias supporting the initiation of its Phase 1 clinical trial
We haven't written up this one. Vietnam Investment Review has the full story — the link below goes straight to it.